Dr. Jack L. Arbiser, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 560
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
GA license 44674
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Metroderm, P.c. (33 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 560
- Services billed
- 3,345
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 851 | 189 |
| Established patient office or other outpatient visit, 20-29 minutes | 499 | 349 |
| Destruction of precancer skin growth, 1 growth | 401 | 271 |
| Destruction of skin growth, 1-14 growths | 286 | 220 |
| Established patient office or other outpatient visit, 10-19 minutes | 156 | 131 |
| Biopsy of related skin growth, first growth | 118 | 109 |
| New patient office or other outpatient visit, 30-44 minutes | 87 | 87 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 39 |
| New patient office or other outpatient visit, 15-29 minutes | 44 | 44 |
| Punch biopsy, first skin growth | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ammonium Lactate Other prescribers in Atlanta, GA | 145 |
| Montelukast Sodium Other prescribers in Atlanta, GA | 143 |
| Clobetasol Propionate Other prescribers in Atlanta, GA | 127 |
| Triamcinolone Acetonide Other prescribers in Atlanta, GA | 101 |
| Ciclopirox (ciclopirox olamine) | 90 |
| Ketoconazole Other prescribers in Atlanta, GA | 45 |
| Mupirocin Other prescribers in Atlanta, GA | 36 |
| Minoxidil Other prescribers in Atlanta, GA | 21 |
| Metronidazole Other prescribers in Atlanta, GA | 20 |
| Doxycycline Hyclate Other prescribers in Atlanta, GA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $231 in total to this clinician.
| Genzyme Corporation | $93.78 |
|---|---|
| Janssen Biotech, Inc. | $64.99 |
| Novartis Pharmaceuticals Corporation | $31.39 |
| Amgen Inc. | $24.01 |
| Galderma Laboratories, L.P. | $16.65 |
| Food and Beverage | $166 |
|---|---|
| Education | $64.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Sep 8, 2025 | Education TREMFYA · Immunology · in-kind | $64.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $137,752 in research payments for these studies, mostly to the institutions running them.
- Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Completed · NCT03889912
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.